Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafenoquine Succinate

FDA-approved product (tablet, oral), marketed as Arakoda, Krintafel.

Registered studies
42
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafenoquine Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria
  • Plasmodium vivax malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafenoquine Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafenoquine Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

    NCT02658435 · start 2016-02-02

    Registered record
    Registry ID
    NCT02658435
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine 150 mg; Matched placebo 150mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-02
    Completion
    2017-09-14
    Enrolment
    486

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine 150 mg; Matched placebo 150mg
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

    NCT02216123 · start 2015-04-30

    Registered record
    Registry ID
    NCT02216123
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine; Tafenoquine Placebo; Chloroquine; Primaquine; Primaquine Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-04-30
    Completion
    2016-11-04
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine; Tafenoquine Placebo; Chloroquine; Primaquine +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate

    NCT02184637 · start 2014-07-31

    Registered record
    Registry ID
    NCT02184637
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine; Dihydroartemisinin + Piperaquine tetraphosphate; Artemether + Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07-31
    Completion
    2015-04-08
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine; Dihydroartemisinin + Piperaquine tetraphosphate; Artemether + Lumefantrine
    PhasePhase 1
    Registry statusCompleted

  • Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

    NCT01376167 · start 2014-04-24

    Registered record
    Registry ID
    NCT01376167
    Conditions
    Malaria, Vivax
    Interventions
    Chloroquine 600mg; Chloroquine 300mg; Tafenoquine 50mg; Tafenoquine 100mg; Tafenoquine 300mg; Tafenoquine 600mg; Primaquine 15mg; Chloroquine 600mg (Part 2 ); Chloroquine 300mg (Part 2 ); Tafenoquine 300mg (Part 2); Primaquine 15mg (Part2 )
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-24
    Completion
    2016-11-18
    Enrolment
    851

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionChloroquine 600mg; Chloroquine 300mg; Tafenoquine 50mg; Tafenoquine 100mg +7 more
    PhasePhase 2
    Registry statusCompleted

  • Tafenoquine Thorough QTc Study in Healthy Subjects

    NCT01928914 · start 2011-07-26

    Registered record
    Registry ID
    NCT01928914
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine 300mg; Tafenoquine 600mg; Tafenoquine 1200mg; moxifloxacin; Placebo for Tafenoquine; Placebo for moxifloxaxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07-26
    Completion
    2012-06-04
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine 300mg; Tafenoquine 600mg; Tafenoquine 1200mg; moxifloxacin +2 more
    PhasePhase 1
    Registry statusCompleted

  • G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)

    NCT01205178 · start 2009-07-02

    Registered record
    Registry ID
    NCT01205178
    Conditions
    Malaria
    Interventions
    Chloroquine; Primaquine; Tafenoquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07-02
    Completion
    2013-04-01
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChloroquine; Primaquine; Tafenoquine
    PhasePhase 1
    Registry statusCompleted

  • Tafenoquine/Chloroquine DDI Study

    NCT00871156 · start 2009-03-24

    Registered record
    Registry ID
    NCT00871156
    Conditions
    Malaria
    Interventions
    Chloroquine, Tafenoquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03-24
    Completion
    2009-08-26
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChloroquine, Tafenoquine; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

    NCT01290601 · start 2003-09-15

    Registered record
    Registry ID
    NCT01290601
    Conditions
    Malaria; Plasmodium Vivax
    Interventions
    Tafenoquine; Chloroquine + Primaquine; tafenoquine; Chloroquine + Primaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2003-09-15
    Completion
    2005-01-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Plasmodium Vivax
    InterventionTafenoquine; Chloroquine + Primaquine; tafenoquine; Chloroquine + Primaquine
    PhasePhase 2
    Registry statusTerminated

  • An Evaluation of Weekly Tafenoquine

    NCT02488980 · start 2000-05

    Registered record
    Registry ID
    NCT02488980
    Conditions
    Falciparum Parasitaemia
    Interventions
    Tafenoquine; Mefloquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-05
    Completion
    2003-03
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFalciparum Parasitaemia
    InterventionTafenoquine; Mefloquine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum

    NCT02488902 · start 1998-08

    Registered record
    Registry ID
    NCT02488902
    Conditions
    Malaria
    Interventions
    Placebo; Tafenoquine 25mg; Tafenoquine 50mg; Tafenoquine 100 mg; Tafenoquine 200 mg; Mefloquine 250 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-08
    Completion
    2003-03
    Enrolment
    521

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionPlacebo; Tafenoquine 25mg; Tafenoquine 50mg; Tafenoquine 100 mg +2 more
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Weekly Tafenoquine

    NCT02491606 · start 1997-05

    Registered record
    Registry ID
    NCT02491606
    Conditions
    Malaria
    Interventions
    Tafenoquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-05
    Completion
    1998-09
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionTafenoquine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Expanded Use in Persistent (B. Microti) Babesiosis

    NCT06478641

    Registered record
    Registry ID
    NCT06478641
    Conditions
    Persistent Babesiosis
    Interventions
    Tafenoquine
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Babesiosis
    InterventionTafenoquine
    PhaseNot recorded
    Registry statusAvailable